Bristol-Myers Squibb news from FierceBiotech
NewsMerck KGaA eyes ImClone, but isn't mystery bidder
Merck KGaA is entering the Bristol-Myers Squibb/ImClone buyout fray. While the German company said it isn't prepared to bid for the whole company, it would be interested in partnering with another... Read more...
ImClone says mystery bidder will be revealed
ImClone says that it expects a mystery bidder to either reject a takeover move or formally offer $6.1 billion for the biotech company. And ImClone says it will name the bidder one way or the other.... Read more...
Icahn to BMS: Your $62 hostile bid is 'absurd'
The letters being exchanged between ImClone Chairman Carl Icahn and Bristol-Myers Squibb CEO Jim... Read more...
BMS fires off $62 offer as it battles for ImClone
If Bristol-Myers Squibb can't charm its way to a merger deal with ImClone, the company seems more than happy to force its way to one. BMS upped its bid slightly to $62 a share--up from $60--and said... Read more...
BMS may just "walk away" from ImClone proposal
Bristol-Myers Squibb is evidently feeling a bit spurned these days, what with a mystery suitor... Read more...
Icahn and Cornelius trade notes, barbs
Bristol-Myers Squibb CEO Jim Cornelius (photo) and ImClone Chairman Carl Icahn were in a... Read more...
Icahn's mystery buyer could spark bidding war
Carl Icahn (photo) all but got out the bull horn yesterday and asked people to step right up and start offering some big numbers... Read more...
ImClone rejects BMS, gets higher bid
Everyone expected it, but now it's official: Bristol-Myers Squibb's $4.5 billion bid for ImClone just isn't enough. ImClone execs brought in JPMorgan to to
BMS, AstraZeneca present saxagliptin data
Bristol-Myers Squibb and AstraZeneca presented results from a 24-week Phase III study of Onglyza (the proposed trade name for saxagliptin). When used in combination with metformin, the drug produced... Read more...
ImClone builds case for higher takeover bid
The executives at ImClone have been carefully crunching the numbers for both its pipeline drugs as well as... Read more...
| Press ReleasesBristol-Myers Squibb Announces Filing of IPO Registration Statement for Mead Johnson Nutrition CompanyBristol-Myers Squibb Announces Filing of IPO Registration Statement for Mead Johnson Nutrition Company NEW YORK--(BUSINESS WIRE)--October 7, 2008--Bristol-Myers Squibb Company (NYSE:BMY) today Read more >> Bristol-Myers Squibb Comments on Eli Lilly as New Erbitux Marketing PartnerBristol-Myers Squibb Comments on Eli Lilly as New Erbitux Marketing Partner Will Receive $1 Billion Upon Completion of Transaction October 6, 2008 PRINCETON, N.J.--(BUSINESS WIRE)--Eli Lilly and Read more >> U.S. Food & Drug Administration Approved the use of REYATAZ® (atazanavir sulfate) Boosted with Ritonavir, in Combination TherapyU.S. Food & Drug Administration Approved the use of REYATAZ® (atazanavir sulfate) Boosted with Ritonavir, in Combination Therapy, for Previously Untreated HIV-1 Infected Adult Patients Read more >> Bristol-Myers Squibb Submits Letter to ImClone Board of DirectorsBristol-Myers Squibb Submits Letter to ImClone Board of Directors NEW YORK, September 11, 2008 - Bristol-Myers Squibb Company (NYSE: BMY) submitted the following letter to ImClone Systems Read more >> ImClone Systems Submits Letter to Bristol-Myers SquibbImClone Systems Submits Letter to Bristol-Myers Squibb NEW YORK--(BUSINESS WIRE)--Sept. 11, 2008--ImClone Systems Incorporated (NASDAQ: IMCL) announced today that Carl Icahn, Chairman of its Board of Read more >> |
Get more Bristol-Myers Squibb coverage at:
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
